Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Enterprise Value (2019 - 2025)

Bioadaptives' Enterprise Value history spans 7 years, with the latest figure at -$59273.0 for Q3 2025.

  • For Q3 2025, Enterprise Value fell 35.04% year-over-year to -$59273.0; the TTM value through Sep 2025 reached -$59273.0, down 35.04%, while the annual FY2024 figure was -$137470.0, 126.19% down from the prior year.
  • Enterprise Value for Q3 2025 was -$59273.0 at Bioadaptives, up from -$210582.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$235.0 in Q2 2024 and bottomed at -$210582.0 in Q2 2025.
  • The 5-year median for Enterprise Value is -$44513.0 (2022), against an average of -$61192.2.
  • The largest annual shift saw Enterprise Value surged 99.41% in 2024 before it plummeted 89509.36% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$83126.0 in 2021, then surged by 69.39% to -$25447.0 in 2022, then crashed by 138.83% to -$60776.0 in 2023, then tumbled by 126.19% to -$137470.0 in 2024, then skyrocketed by 56.88% to -$59273.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Enterprise Value are -$59273.0 (Q3 2025), -$210582.0 (Q2 2025), and -$39564.0 (Q1 2025).